Commodore Capital LP Has $54.21 Million Stock Holdings in Pharvaris N.V. $PHVS

Commodore Capital LP lifted its position in shares of Pharvaris N.V. (NASDAQ:PHVS) by 1.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,918,970 shares of the company’s stock after purchasing an additional 29,525 shares during the period. Pharvaris comprises 3.1% of Commodore Capital LP’s investment portfolio, making the stock its 13th largest holding. Commodore Capital LP’s holdings in Pharvaris were worth $54,211,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PHVS. Wellington Management Group LLP bought a new position in Pharvaris in the 3rd quarter valued at approximately $43,282,000. Paradigm Biocapital Advisors LP increased its position in Pharvaris by 72.7% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after acquiring an additional 772,583 shares during the period. Balyasny Asset Management L.P. acquired a new position in Pharvaris in the 3rd quarter valued at approximately $15,613,000. Elmind Capital LP bought a new position in shares of Pharvaris during the fourth quarter valued at $13,202,000. Finally, Eversept Partners LP bought a new position in shares of Pharvaris during the fourth quarter valued at $12,187,000.

Wall Street Analyst Weigh In

Several analysts recently weighed in on PHVS shares. Citigroup reissued a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Royal Bank Of Canada lowered their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Wedbush lifted their target price on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Wall Street Zen lowered Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pharvaris has an average rating of “Moderate Buy” and an average price target of $50.08.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $34.17 on Monday. The business’s 50 day simple moving average is $32.45 and its two-hundred day simple moving average is $29.27. The firm has a market cap of $2.24 billion, a P/E ratio of -10.75 and a beta of -2.34. Pharvaris N.V. has a 52-week low of $19.12 and a 52-week high of $36.60.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, equities analysts forecast that Pharvaris N.V. will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling at Pharvaris

In related news, CEO Berndt Modig sold 2,291 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $31.07, for a total transaction of $71,181.37. Following the completion of the sale, the chief executive officer owned 135,209 shares in the company, valued at approximately $4,200,943.63. This represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Anna Nijdam sold 2,670 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $30.87, for a total transaction of $82,422.90. Following the completion of the sale, the insider owned 46,275 shares of the company’s stock, valued at approximately $1,428,509.25. The trade was a 5.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 274,555 shares of company stock worth $8,880,601 in the last ninety days.

Pharvaris Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.